ORIGINAL ARTICLE

I. Günaydin · P. L. Pereira · J. Fritz · C. König I. Kötter

Magnetic resonance imaging guided corticosteroid injection of sacroiliac joints in patients with spondylarthropathy. Are multiple injections more beneficial?

Received: 18 August 2004 / Accepted: 8 May 2005 / Published online: 12 July 2005 © Springer-Verlag 2005

Abstract Efficacy of a second magnetic resonance (MR) imaging guided corticosteroid injection of inflamed sacroiliac joints (SIJ) in patients with spondylarthropathy. Thirty-one patients received 50 injections in an outpatient basis. Fifteen of 31 patients who relapsed or were non-responders received a second injection. All had MR-guided injection of 40 mg triamcinolone acetonide into SIJ using an open 0.2 Tesla unit. Twenty of 31 patients after the first injection, and 9 of 15 patients after the second injection reported subjective improvement, which lasted for a mean of 8.7 ± 10.9 and 16.1 ± 15.8 months for each group. Subchondral bone marrow edema resolved in 15 of 20 patients who reported subjective improvement, after the first injection. No complications occurred. MR guided steroid injection of SIJ is effective and safe. Since there is no exposure to radiation it could be performed many times. Repeated injections seem to be beneficial for primary nonresponders and patients who relapsed.

Keywords Magnetic resonance imaging · Corticosteroid reinjection · Spondylarthropathy · Sacroiliac joints

Introduction

Spondarthropathies (SpA) are a heterogenous group of inflammatory disorders, which mainly affect the spine

Department of Internal Medicine II (Hematology, Oncology, Immunology and Rheumatology), University Hospital, Eberhard-Karls-University, Otfried-Müller-Straße 10, 72076 Tübingen, Germany E-mail: ilhan.guenaydin@med.uni-tuebingen.de Tel.: +49-7071-2984095 Fax: +49-7071-292763

P. L. Pereira · J. Fritz · C. König Department of Radiology, University Hospital, Eberhard-Karls-University, 72076 Tübingen, Germany and entheses and usually begin in young adults. Inflammation of one or both sacroiliac joints (SIJ) and inflammatory back pain are typical features of SpA [1, 2]. The treatment of SpA is still inadequate and consists mainly of non-steroidal anti-inflammatory drugs (NSAID) and physiotherapy. The disease modifying anti-rheumatic drugs (DMARD) are not clearly effective, especially in axial disease [3]. In recent studies, treatment with anti-TNF- α -agents resulted in significant and sustained improvement but whether they will prevent the structural damage remains to be shown [4–7].

The therapy of sacroiliitis with local steroid injection is safe and effective [8–11]. In a previous work, we showed that the magnetic resonance (MR) imaging is a suitable and safe technique for local corticosteroid injection of SIJ [12]. Here, we present our preliminary experiences with special focus on repetitive injection of corticosteroids. In this small sample, we confirmed the feasibility of MR guided steroid administration into the SIJ and assessed the efficacy of a second injection in non-responders and patients who relapsed.

Materials and methods

Thirty-one patients fulfilling the modified New York and European spondylarthropathy study group criteria [13, 14] were included in the study (18 men, 13 women, mean age at onset: 24.7 ± 7.9 years). All patients had been taking NSAID and/or DMARD without adequate control of complains for at least 6 months. They had persistent inflammatory back pain which was poorly controlled. Inflammatory back pain was defined as by Calin et al. [15]. Nineteen of 31 patients were HLA-B27 positive. All injections were performed on an outpatient basis. Twelve patients were injected unilaterally. All patients provided written informed consent and the investigations have been performed in accordance with the principles of the Helsinki Declaration.

The conventional radiographic degree of sacroiliitis was not evaluated. Only patients with subchondral bone

I. Günaydin (🖂) · I. Kötter

Table 1 Patients' characteristics before intraarticular treatment

| Patient | Sex | Age at onset (years) | Disease duration (years) | HLA-B 27 | Mennell's sign | ESR (mm/h) | CRP (mg/dl) | Edema on MRIa |
|---------|-----|----------------------|--------------------------|----------|----------------|------------|-------------|---------------|
| 1 | М | 29 | 10 | + | _ | 8 | 0.2 | + + |
| 2 | Μ | 10 | 17 | + | + | 20 | 5.39 | + + |
| 3 | М | 25 | 10 | + | + | 8 | 2.25 | + + |
| 4 | Μ | 15 | 10 | + | + | 6 | 2.84 | + + |
| 5 | Μ | 24 | 2 | _ | + | 20 | 0.2 | + + |
| 6 | F | 25 | 3 | + | + | 4 | 0.2 | + + |
| 7 | Μ | 35 | 6 | + | _ | 9 | 0.2 | + + |
| 8 | F | 32 | 2 | _ | - | 2 | 0.2 | + + + |
| 9 | F | 32 | 28 | _ | + | 32 | 3.20 | + + |
| 10 | F | 24 | 5 | + | + | 20 | 0.2 | + + + |
| 11 | F | 23 | 10 | + | + | 29 | 1.29 | + + |
| 12 | М | 23 | 1 | + | - | 6 | 0.2 | + + |
| 13 | Μ | 22 | 3 | + | + | 96 | 10.76 | + + |
| 14 | Μ | 19 | 10 | + | + | 20 | 2.95 | + + |
| 15 | F | 13 | 12 | + | + | 13 | 0.78 | + + + |
| 16 | Μ | 25 | 2 | + | + | 66 | 1.18 | + + |
| 17 | Μ | 28 | 2 | + | + | 3 | 0.2 | + + |
| 18 | Μ | 28 | 13 | _ | + | 38 | 3.32 | + + + |
| 19 | F | 30 | 16 | + | + | 20 | 0.93 | + + |
| 20 | F | 58 | 3 | _ | + | 6 | 0.2 | + + |
| 21 | Μ | 55 | 10 | _ | + | 6 | 1.31 | + |
| 22 | F | 19 | 2 | _ | + | 36 | 3.30 | + + |
| 23 | Μ | 22 | 11 | + | + | 8 | 0.5 | + + |
| 24 | F | 25 | 2 | + | + | 6 | 0.2 | + + + |
| 25 | Μ | 19 | 2 | _ | - | 8 | 1.17 | + + |
| 26 | Μ | 18 | 3 | _ | + | 16 | 1.32 | + + |
| 27 | F | 27 | 13 | _ | - | 9 | 0.2 | + + + |
| 28 | F | 30 | 2 | _ | + | 6 | 1.2 | + |
| 29 | F | 11 | 6 | + | _ | 7 | 0.2 | + + |
| 30 | Μ | 23 | 5 | _ | - | 6 | 0.2 | + + |
| 31 | Μ | 25 | 2 | + | + | 7 | 0.2 | + + |

a + slight, + + moderate, + + + marked edema.

marrow edema on MR imaging and refractory pain were included in the study. The following grading system was used for MR evaluation: + slight edema, + + moderate edema and + + + marked edema. Table 1 shows patient characteristics before corticosteroid injection of the SIJ.

All patients had MR guided injection of 40 mg triamcinolone acetonide into each inflamed SIJ with a MR compatible therapy needle (0.9×100-mm Somatex, Berlin, Germany) using an open 0.2 Tesla unit (MR open: Siemens, Erlangen, Germany). Patients who relapsed and the non-responders received a second injection. The time interval between the first and the second injection was at least 3 months. The corticosteroid injections were done according to a protocol, which was described in detail elsewhere [12].

The clinical examinations were done at the beginning and every 6–10 weeks for a minimum of 12 months. Mennell's sign [16] and the anterior flexibility of the lumbar spine, according to the Schober method [17], were assessed. The degree of inflammatory back pain was assessed by a visual analog scale (VAS) with a range from 0 to 10 (most severe pain: 10). The patient was defined as a responder, if the subjective pain index showed at least 50% improvement on VAS.

A high-field MR examination of SIJ was done before and 3 months after each corticosteroid injection using a 1.5 Tesla unit (Magnetom Sonata or Magnetom Vision; Siemens) with T1 weighted images (TR/TE: 430/12 ms) and T2 weighted images (TR/TE: 3300/17–120 ms, slice thickness 4 mm). Fat suppressed inversion recovery sequences were additionally performed with TR/TE/TI: 4800/22–90/180 ms and 4 mm slice thickness. The laboratory examinations including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), HLA-B27 and anti-nuclear antibody (ANA) were performed by conventional methods.

Results

Twenty of 31 patients after the first injection and 9 of 15 patients after the second injection reported subjective improvement, which lasted for a mean of 8.7 ± 10.9 and 16.1 ± 15.8 months for each group, respectively (Figs. 1 and 2). The mean VAS values were 7.9 ± 1.2 before the first injection (n=31), 4.1 ± 2.5 after the first injection (n=15), respectively.

After the first injection, the subchondral bone marrow edema resolved in 15 of 20 patients who reported subjective improvement, whereas it resolved in 5 of 11 patients who were non-responders. The subcondral bone



Fig. 1 Subjective back pain index in 20 of 31 patients who benefited from the first intra-articular injection (0 pain, 10 very severe pain)

marrow edema resolved in four of nine patients who were responders after the second injection.

There were no significant differences in assessment of laboratory parameters including CRP and ESR, before and after treatment. In 16 patients CRP and in 12 patients ESR were elevated (normal < 0.6 mg/dl and < 15 mm/h) and did not change significantly after the local steroid injections. The mean values before, after the first and after the second infitrations for CRP were: 1.5 ± 2.1 , 0.9 ± 1.0 and 1.2 ± 1.0 and for ESR: 15.3 ± 14.7 , 12.7 ± 10.6 and 15.6 ± 13.0 , respectively. In one patient, the initially high ESR and CRP measure-

ments (96 mm/h and 10.76 mg/dl) returned to normal levels after a single injection of both SIJ. There was no correlation between clinical findings and laboratory pararmeters.

Only one of three patients with concomitant fibromyalgia responded to local steroid injection. Mennell's sign was improved in 16 of 31 patients, whereas the Schober test was unchanged in all patients. Nearly half of the patients reported gastrointestinal intolerance to NSAID (two patients with inflammatory bowel disease). In 13 patients, the NSAID therapy could be stopped. The local treatment was well tolerated and no adverse events were noticed. Three patients described the procedure as painful or very painful. Five patients reported transient increase of pain for about 24 h.





Discussion

The mean duration between the first clinical signs of sacroiliitis and the development of radiological changes in the SIJ varies between 5 years and 9 years [18, 19]. However, an early diagnosis is essential since it may help ensure patient education, avoidance of unnecessary investigation and more important induce early and effective treatment.

Early sacroiliitis can be demonstrated by MR imaging in SpA before the abnormalities are seen by conventional radiography. At present, MR imaging is considered to be the best technique able to demonstrate both, acute and chronic changes in SIJ. It is the most sensitive and specific method to evaluate SIJ in terms of inflammation [20–22].

Although high costs and the relatively long duration of this procedure limit its use, MR seems to be suitable not only in diagnosing but also managing sacroiliitis. In a previous work, we showed for the first time, that interventional MR is a useful and safe method for local steroid injection of the SIJ [12]. In that small pilot study the inflammatory low back pain could be reduced for a mean duration of 10 months. It is important to note that this technique is not associated with irradiation and no serious side effects have been observed.

In this study, we present our experience with more patients confirming our former data. Since this method is safe and without irradiation, the non-responders and the patients who relapsed received a second injection. The laboratory findings including CRP and ESR did not change significantly, irrespective of whether the patients were responders or not, which means the injections showed no systemic effects. An interesting result of the present study was, that the patients with a second steroid injection reported longer subjective improvement than the patients with only one injection $(16.1 \pm 15.8 \text{ versus})$ 8.7 ± 10.9 months). In addition, some patients showed a partial reduction in inflammation on MR imaging, which could mean that the dosage of corticosteroid was not sufficient. We do not know whether a higher dosage of local steroids, i.e. 80-100 mg, could lead to better results. Of course, shortcomings of our study are the small sample size, heterogeneity of the patients and lack of randomisation and of a placebo treated control group. Furthermore, dynamic magnetic resonance imaging which needs application of the contrast agent gadolinium-DTPA intravenously could be a more specific method to diagnose and to follow-up sacroiliitis [11].

Luukkainnen et al. [23] evaluated the efficacy of periarticular corticosteroid injection in patients with sacroiliitis. They showed in their double blind controlled study that periarticular corticosteroid treatment of the SIJ is effective; however, the number of patients in their study was low. Although the results of their study are preliminary they are encouraging. In our study, we could reduce the time needed for steroid infiltration of SIJ to
 Table 2 Patient groups suitable for a MR-guided steroid injection of sacroiliac joints

Isolated sacroiliitis Young patients Patients with drug intolerance and allergy to contrast agents Spondarthropathy concomitant with inflammatory bowel disease

approximately 30 min for bilateral injections depending on the individual patient. Since we need less time to perform a periarticular infiltration, it is important to compare it with intraarticular injections.

Bollow et al. [24] performed computed tomography (CT) guided intraarticular steroid injection into the SIJ of children and observed clear clinical improvement. They pointed out that this technique has to be performed by experienced hands in order to minimize the length of the procedure, since radiation exposure is a concern in children. In this group of patients, MR-guided steroid injection could be a logical option as well as in patients with inflammatory bowel disease, drug intolerance or allergy to contrast agents (Table 2).

TNF- α is the key proinflammatory cytokine involved in the pathological inflammatory processes of ankylosing spondylitis [25]. Using CT guided sacroiliac biopsies Braun et al. [26] showed that TNF- α -RNA is increased in inflamed SIJ of patients with SpA. In recent studies, TNF- α -blocking agents induced dramatic improvement of enthesitis and associated osteitis as shown on MRI [4, 27]. These findings suggest that $TNF-\alpha$ -blockade is not only effective in suppressing synovitis, but also in enthesitis, the hallmark of SpA. However, some serious adverse events, i.e. severe infections, malignancies, demyelinating disorders, congestive heart failure and hypersensitivity reactions need to be considered. In order to prevent such side effects, a useful option would be the local application of these potentially effective agents [28]. Recently, Kellner et al. [29] reported that local injection of infliximab into SIJ is safe and technically feasible. They installed 60 mg infliximab in the inflamed SIJ of five patients with ankylosing spondylitis. Inflammatory pain improved in all patients and MR imaging showed a decrease of subchondral bone edema. Local application of these substances in sacroiliitis is a promising idea and should be tested in future controlled trials.

In conclusion, MR guided local steroid injection is effective and safe, carrying no risks in skilled hands. It could be performed many times without drawbacks of radiation exposure. Repeated injections seem to be more beneficial. Future controlled studies should determine, whether MR guided steroid injections result in significantly more clinical improvement compared to the conventional methods.

References

Vernon-Roberts B (1998) Spondarthropathies. In: Klippel JH, Dieppe PA (eds) Rheumatology. Mosby, London 6(18):1–6

- Cuellar ML, Espinoza LR (1996) Management of spondarthropathies. Curr Opin Rheumatol 8:288–295
- Dougados M et al (1998) Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baillieres Clin Rheumatol 12:717–736
- 4. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P (2001) Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy. Arthritis Rheum 44:2112–2117
- Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H et al (2002) Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 29:959–965
- Braun J, Brandt J, Listing J, Zink A, Alten R et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187–1193
- Gorman JD, Sack KE, Davis JC (2002) Treatment of ankylosing spondylitis by inhibition of tumor necroisis factor α. N Engl J Med 346:1349–1356
- Maugars Y, Mathis C, Vilon P, Prost A (1992) Corticosteroid injection of the sacroiliac joint in patients with seronegative spondylarthropathy. Arthritis Rheum 35:564–568
- Maugars Y, Mathis C, Berthelot JM, Charlier C, Prost A (1996) Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol 35:767–770
- Hendrix RW, Lin PP, Kane WJ (1982) Simplified aspiration or injection technique for the sacro-iliac joint. J Bone Joint Surg Am 64:1249–1252
- Braun J, Bollow M, Seyrekbasan F, Häberle HJ, Eggens U, Mertz A et al (1996) Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondylarthropathy with sacroiliitis: clinical outcome and follow-up by dynamic magnetic resonance imaging. J Rheumatol 23:659– 664
- 12. Günaydin I, Pereira PL, Daikeler T, Mohren M, Trübenbach J et al (2000) Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondylarthropathy: a pilot study. J Rheumatol 27:424– 428
- Van der Linden SM, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368
- 14. Dougados M, Van der Linden SM, Juhlin R, Huitfeldt B, Amor B, Calin A et al (1991) The European spondylarthropathy study group: the European spondylarthropathy study group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218–1227
- Calin A, Porta J, Fries JF, Schurmann DJ (1977) Clinical history as a screening test for ankylosing spondylitis. JAMA 237:2613–2614

- Mennell JB (1977) Treatment by movement, manipulation and massage. JA Churchill, London
- Schober P (1937) Lendenwirbelsäule und Kreuzschmerzen. Münch Med Wochenschr 84:336–428
- Gran JT, Husby G (1993) The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum 22:319–334
- Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W, Deicher H (1988) Clinical features and prognosis of patients with possible ankylosing spondylitis: results of a 10year followup. J Rheumatol 15:1109–1114
- 20. Blum U, Buitrago-Tellez C, Mundinger A, Krause T, Laubenberger J, Vaith P et al (1996) Magnetic resonance imaging (MRI) for detection of active sacroiliitis—a prospective study comparing conventional radiography, scintigraphy, and contrast enhanced MRI. J Rheumatol 23:2107–2115
- Oostveen J, Prevo R, den Boer J, van de Laar M (1999) Early detection of Sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. J Rheumatol 26:1953–1958
- 22. Braun J, Bollow M, Eggens U, König H, Distler A, Sieper J (1994) Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 7:1039–1045
- 23. Luukkainen R, Nissilä M, Asikainen E, Sanila M, Lehtinen K et al (1999) Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy. Clin Exp Rheumatol 17:88–90
- 24. Bollow M, Biedermann T, Kannenberg J, Paris S, Schauer-Petrowski C, Minden K et al (1998) Use of dynamic magnetic resonance imaging to detect sacroiliitis in HLA-B27 positive and negative children with juvenile arthritides. J Rheumatol 25:556–564
- 25. Stone MA, Payne U, Pacheco-Tena C, Inman RD (2004) Cytokine correlates of lincial response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 63:84–87
- 26. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499–505
- Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J et al (2002) Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience. Ann Rheum Dis 61(Suppl III):iii51-iii60
- Nikas SN, Temekonidis TI, Zikou AK, Argyropoulou MI, Efremidis S, Drosos AA (2004) Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study. Ann Rheum Dis 63:102–103
- Kellner H, Kroetz M, Schattenkirchner M, Kellner W (2002) Successful therapy of sacroiliitis in AS patients by intraarticular injection of infliximab. Arthritis Rheum 46:S431–1127